{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T19:09:11Z","timestamp":1694632151091},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1157\/13119881","type":"journal-article","created":{"date-parts":[[2008,5,14]],"date-time":"2008-05-14T05:50:06Z","timestamp":1210744206000},"page":"289-292","source":"Crossref","is-referenced-by-count":5,"title":["Mononucleosis infecciosa en pacientes con enfermedad inflamatoria intestinal en tratamiento con azatioprina"],"prefix":"10.1016","volume":"31","author":[{"given":"Ana","family":"Bargall\u00f3","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Carri\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugeni","family":"Dom\u00e8nech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Antonio Ar\u00e9valo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00edriam","family":"Ma\u00f1osa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Cabr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Luis Cabriada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miquel","family":"\u00c0ngel Gassull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13119881_bb0010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0210-5705(02)79028-6","article-title":"Indicaciones de la azatioprina (o 6-mercaptopurina) en la enfermedad inflamatoria intestinal","volume":"25","author":"Cabr\u00e9","year":"2006","journal-title":"Gastroenterol Hepatol"},{"key":"10.1157\/13119881_bb0015","first-page":"247","article-title":"Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice","volume":"10","author":"Cara","year":"2004","journal-title":"Med Sci Monit"},{"key":"10.1157\/13119881_bb0020","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0210-5705(02)70275-6","article-title":"Preguntas y respuestas sobre el papel de la azatioprina y la 6-mercaptopurina en el tratamiento de la enfermedad inflamatoria intestinal","volume":"25","author":"Gisbert","year":"2002","journal-title":"Gastroenterol Hepatol"},{"key":"10.1157\/13119881_bb0025","first-page":"423","article-title":"A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate","volume":"91","author":"Sandborn","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1157\/13119881_bb0030","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1053\/j.gastro.2005.03.031","article-title":"A randomized, double-blind, controlled withdrawal trial in Crohn\u2019s disease patients in long-term remission with azathioprine","volume":"128","author":"L\u00e9mann","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1157\/13119881_bb0035","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1365-2036.2004.01944.x","article-title":"Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn\u2019s disease: increasing relapse rate the following year","volume":"19","author":"Villien","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13119881_bb0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0210-5705(03)70335-5","article-title":"Infecciones oportunistas en pacientes con enfermedad inflamatoria intestinal bajo tratamiento inmunosupresor","volume":"26","author":"Bernal","year":"2003","journal-title":"Gastroenterol Hepatol"},{"key":"10.1157\/13119881_bb0045","first-page":"257","article-title":"Clinical consequences of Epstein-Barr virus infection and possible control by an anti-viral vaccine","volume":"53","author":"Epstein","year":"1983","journal-title":"Clin Exp Immunol"},{"key":"10.1157\/13119881_bb0050","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/rmv.505","article-title":"Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency?","volume":"16","author":"Kimura","year":"2006","journal-title":"Rev Med Virol"},{"key":"10.1157\/13119881_bb0055","unstructured":"Sandborn WJ, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azatioprina o 6-mercaptopurina para la inducci\u00f3n de la remisi\u00f3n en la enfermedad de Crohn (Revisi\u00f3n Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 N\u00famero 1. Oxford: Update Software Ltd. Disponible en: http:\/\/www.update-software.com (traducida de The Cochrane Library. Issue 1. Chichester: John Wiley & Sons, Ltd.; 2007)."},{"key":"10.1157\/13119881_bb0060","unstructured":"Pearson DC, May GR, Fick G, Sutherland LR. Azatioprina para el mantenimiento de la remisi\u00f3n en la enfermedad de Crohn (Revisi\u00f3n Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 N\u00famero 1. Oxford: Update Software Ltd. Disponible en: http:\/\/www.update-software.com (traducida de The Cochrane Library. Issue 1. Chichester: John Wiley & Sons, Ltd.; 2007)."},{"key":"10.1157\/13119881_bb0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/gut.2005.068809","article-title":"Ramdomised, controlled trial, of azathioprine and 5-aminosalicylic acid for the treatment of steroid-dependent ulcerative colitis","volume":"55","author":"Ardizzone","year":"2006","journal-title":"Gut"},{"key":"10.1157\/13119881_bb0070","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1046\/j.1365-2036.2002.01385.x","article-title":"Azathioprine without oral cyclosporine in the long-term maintenance of remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis","volume":"16","author":"Dom\u00e8nech","year":"2002","journal-title":"Aliment Ther Pharmacol"},{"key":"10.1157\/13119881_bb0075","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-111-8-641","article-title":"6-mercaptopurine in the management of the inflammatory bowel disease: short and long-term toxicity","volume":"111","author":"Present","year":"1989","journal-title":"Ann Int Med"},{"key":"10.1157\/13119881_bb0080","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/gut.50.4.485","article-title":"The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review","volume":"50","author":"Fraser","year":"2002","journal-title":"Gut"},{"key":"10.1157\/13119881_bb0085","unstructured":"Navarro Ortega D. Diagn\u00f3stico de la mononucleosis infecciosa causada por el virus de Epstein-Barr. Servicio de Microbiolog\u00eda. Hospital Cl\u00ednico Universitario. Valencia. Control de Calidad de la Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica (SEIMC). Disponible en: http:\/\/www.seimc.org\/control\/revi_Sero\/veb.htm"},{"key":"10.1157\/13119881_bb0090","first-page":"7","article-title":"Mononucleosis infecciosa mortal durante el tratamiento con azatioprina en la enfermedad de Crohn","volume":"23","author":"Garrido Serrano","year":"2000","journal-title":"Gastroenterol Hepatol"},{"key":"10.1157\/13119881_bb0095","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/gut.36.2.311","article-title":"Fatal infectious mononucleosis: a severe complication in the treatment of Crohn\u2019s disease with azathioprine","volume":"36","author":"Posthuma","year":"1995","journal-title":"Gut"},{"key":"10.1157\/13119881_bb0100","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0025-7753(03)73807-X","article-title":"S\u00edndrome febril por infecci\u00f3n por el virus del Epstein-Barr en la enfermedad de Crohn","volume":"120","author":"Lobo","year":"2003","journal-title":"Med Clin (Barc)"},{"key":"10.1157\/13119881_bb0105","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/01.MIB.0000225333.83861.16","article-title":"Reactive hemophagocytic syndrome complicating the treatment of inflammatory bowel disease","volume":"12","author":"James","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1157\/13119881_bb0110","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1157\/13111681","article-title":"Optimizaci\u00f3n del tratamiento inmunomodulador con azatioprina o 6-mercaptopurina en pacientes con enfermedad inflamatoria intestinal","volume":"30","author":"Bastida","year":"2007","journal-title":"Gastroenterol Hepatol"},{"key":"10.1157\/13119881_bb0115","first-page":"4253","article-title":"Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and the role of Epstein-Barr virus","volume":"41","author":"Hanto","year":"1981","journal-title":"Cancer Res"},{"key":"10.1157\/13119881_bb0120","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199305063281806","article-title":"Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis","volume":"328","author":"Kamel","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1157\/13119881_bb0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00002018-200023020-00002","article-title":"Post-transplant malignancy: the role of immunosupression","volume":"23","author":"Penn","year":"2000","journal-title":"Drug Saf"},{"key":"10.1157\/13119881_bb0130","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/ibd.20211","article-title":"Lymphoma risk in inflammatory bowel disease: is it the disease or its trreatment?","volume":"13","author":"Jones","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1157\/13119881_bb0135","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/gut.2004.051771","article-title":"Risk of haematopoietic cancer in patients with inflammatory bowel disease","volume":"54","author":"Askling","year":"2005","journal-title":"Gut"},{"key":"10.1157\/13119881_bb0140","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1046\/j.1365-2036.2001.01023.x","article-title":"Review article: the risk of lymphoma associated to inflammatory bowel disease and immunosuppressive treatment","volume":"15","author":"Aithal","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13119881_bb0145","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"10.1157\/13119881_bb0150","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/gast.2002.30328","article-title":"Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine","volume":"122","author":"Dayharsh","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1157\/13119881_bb0155","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00054725-200407000-00015","article-title":"Epstein-Barr virus-associated lymphoma in Crohn\u2019s disease","volume":"10","author":"Losco","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1157\/13119881_bb0160","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM199409293311321","article-title":"Reversible lymphoma in the setting of azathioprine therapy for Crohn\u2019s disease","volume":"331","author":"Larvol","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1157\/13119881_bb0165","doi-asserted-by":"crossref","first-page":"424","DOI":"10.5858\/2001-125-0424-PEBVAH","article-title":"Primary Epstein-Barr virus-associated Hodgkin disease complicating of the ileum complicating Crohn disease","volume":"125","author":"Li","year":"2001","journal-title":"Arch Pathol Lab Med"},{"key":"10.1157\/13119881_bb0170","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.bmt.1705289","article-title":"Preemptive diagnosis and treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development","volume":"37","author":"Weinstock","year":"2006","journal-title":"Bone Marrow Transpl"},{"key":"10.1157\/13119881_bb0175","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00054725-200403000-00004","article-title":"Epstein-Barr virus load in Crohn\u2019s disease. Effect of immunosuppressive therapy","volume":"10","author":"Reijasse","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1157\/13119881_bb0180","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/ibd.20131","article-title":"Infliximab and the risk of latent virases reactivation in active Crohn\u2019s disease","volume":"13","author":"Lavagna","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1157\/13119881_bb0185","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1586\/14787210.5.3.403","article-title":"Advanced therapeutic and prophylactic strategies for Epstein-Barr virus infection in immunocompromised patients","volume":"5","author":"Okano","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1157\/13119881_bb0190","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1111\/j.1600-6143.2005.01115.x","article-title":"Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients","volume":"5","author":"Funch","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1157\/13119881_bb0195","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1182\/blood.V99.12.4364","article-title":"Prevention of Epstein-Barr virus lymphoprolifertaive disease by molecular monitoring and preemptive rituximab in high-risk patients after allogenic stem cell transplantation","volume":"99","author":"Van Esser","year":"2002","journal-title":"Blood"},{"key":"10.1157\/13119881_bb0200","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2165\/00003495-200464240-00004","article-title":"Viral prophylaxis in organ transplant recipients","volume":"64","author":"Slifkin","year":"2004","journal-title":"Drugs"},{"key":"10.1157\/13119881_bb0205","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1182\/blood-2002-10-3092","article-title":"Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma","volume":"101","author":"Duraiswamy","year":"2003","journal-title":"Blood"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570508713037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570508713037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T13:36:18Z","timestamp":1631280978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570508713037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0210570508713037"],"URL":"https:\/\/doi.org\/10.1157\/13119881","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}